Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A

British Journal of Dermatology

Volumn 152, Issue 2, 2005, Pages 342-345

  Weber, A ^a   Heger, S ^b   Sinkgraven, R ^c   Heckmann, M ^d   Elsner, P ^e   Rzany, B ^c  

^a Faculty of Medicine Mannheim   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Praxisklinik F Dermatol Starnberg   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Botulinum toxin A; Hyperhidrosis; Psychosocial aspects; Social phobia

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ANALYTIC METHOD; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; FOCAL HYPERHYDROSIS; GRAVIMETRY; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SOCIAL PHOBIA; SOCIAL PSYCHOLOGY; STANDARDIZATION; STATE TRAIT ANXIETY INVENTORY; TREATMENT OUTCOME;

ADULT; ANXIETY; BOTULINUM TOXIN TYPE A; DEPRESSION; FEMALE; HUMANS; HYPERHIDROSIS; INTERPERSONAL RELATIONS; MALE; NEUROMUSCULAR AGENTS; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 14844312850     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06334.x     Document Type: Article

References (15)

1. Lopez M, Sessler DI, Walter K et al. Rate and gender dependence of the sweating, vasoconstriction, and shivering tresholds in humans. Anesthesiology 1994; 80:780-8.
2. Leung AK, Chan PY, Choy MC. Hyperhidrosis. Int J Dermatol 1999; 38:561-7.
3. Odderson IR. Axillary hyperhidrosis: treatment with botulinum toxin A. Arch Phys Med Rehabil 1998; 79:350-2.
4. Heckmann M, Rzany B. Botulinumtoxin in der Dermatologie. Grundlagen und Praktische Anwendung. Munich: Urban und Vogel, 2002.
5. Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001; 8:247-52.
6. Laux L, Glanzmann P, Schaffner P, Spielberger CD. Das State-Trait-Angstinventar (STAI). Weinheim: Beltz Testgesellschaft, 1981.
7. Franke GH. SCL-90-R. Die Symptom-Checkliste von Derogatis - Deutsche Version - Manual. Göttingen: Beltz Testgesellschaft, 1995.
8. Hermann C, Buss U, Snaith RP. HADS-D. Hospital Anxiety and Depression Scale - Deutsche Version. Ein Fragebogen zur Erfassung von Angst und Depressivität in der Somatischen Medizin. Bern: Verlag Hans Huber, 1995.
9. Stangier U, Heidenreich T, Berardi A et al. Die Erfassung sozialer Phobie durch die Social Interaction Anxiety Scale (SIAS) und die Social Phobia Scale (SPS). Z Klin Psychol 1999; 28:28-36.
10. Chren MM, Lasker RJ, Quinn LM et al. Skindex, a quality of life measure for patients with skin diseases: reliability, validity and responsiveness. J Invest Dermatol 1996; 107:707-13.
11. Chren MM, Sasek RJ, Flocke SA et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality of life instrument for patients with skin diseases. Arch Dermatol 1997; 133:1433-40.
12. Naumann MK, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Ann Neurol 2002; 52:247-50.
13. 3 Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998; 134:454-8.
14. Higaki Y, Kawamoto K, Kamo T et al. The Japanese version of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol 2002; 29:693-8.
15. Bland JM, Altman DG. Statistic notes: regression towards the mean. BMJ 1994; 308:1499.